Clinical trial · Observational
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
NCT05265429CI-TRIAL-00096870recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to learn more about lung cancer (NSCLC or SCLC) diagnosed in adults at ages 45 or younger.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| NUT Carcinoma | NUT Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Small Cell Lung Carcinoma | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data and Specimen Collection | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Data/Biospecimen Collection
- description
- Tumor and saliva specimens from participants with non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) diagnosed at age 45 or younger
- interventionNames
- Genetic: Data and Specimen Collection
Primary outcomes (1)
- measure
- Repository of specimens and data
- timeFrame
- 5 years or study closure
- description
- Prospective registry of young lung cancer specimens for exploratory tumor and germline genomics, transcriptomics/proteomics, and future biomarker study.
Secondary outcomes (3)
- measure
- Number of patients with targetable somatic alterations in known oncogenic driver genes
- timeFrame
- 5 years or study closure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Age 45 and under at lung cancer diagnosis * Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC of any stage) at any treatment time point * Provision of written informed consent * Willingness to undergo no more than two (2) peripheral blood draws in a four (4) week period, with no more than 50 ml peripheral blood collected over eight (8) weeks * Individuals under age 18 are eligible for study if they meet defined criteria; in addition, consent for participation must be given by a legal guardian or parent Exclusion Criteria: * Individuals who decline to sign consent * Individuals who are unable to give consent or assent and are without a designated healthcare proxy * Compromise of patient diagnosis or staging if tissue is used for research
References
Publications (0)
Data not yet available
No reference posted for this study.